| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean supine DBP 95‐115 mm Hg at 2 separate visits following discontinuation or tapering of antihypertensive medication (all patients had received antihypertensive therapy that was discontinued during the first 2 weeks of placebo run‐in); 4‐week double‐blind treatment; 1‐week single‐blind placebo washout period |
| Participants |
Fosinopril 10 mg: n=17(4 males,13 females); mean age=49(9.1) years; baseline supine SBP=163.8 mm Hg, DBP=102.2 mm Hg; baseline HR=77.4 bpm;
Fosinopril 20 mg: n=15(6 males,9 females); mean age=55(8.1) years; baseline supine SBP=161.2 mm Hg, DBP=100.2 mm Hg; baseline HR=73.9 bpm;
Fosinopril 40 mg: n=16(9 males,7 females); mean age=51(9.6) years; baseline supine SBP=164.4 mm Hg, DBP=101.8 mm Hg; baseline HR=77.8 bpm;
Placebo: n=16(0 males,16 females); mean age=56(14) years; baseline supine SBP=154.7 mm Hg, DBP=99.8 mm Hg; baseline HR=74.2 bpm |
| Interventions |
Fosinopril 10 mg once daily,
Fosinopril 20 mg once daily,
Fosinopril 40 mg once daily,
Placebo;
administered in morning |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
Trough HR;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP reported, endpoint SD not reported; imputed overall trial mean SBP and DBP SD of change; BP data from Table II, p. 327; trough and peak BP data also available in Figures 1 and 2, p.327; 2 sets of baseline BP are reported; Jadad score=3; funding source= Bristol‐Myers Squibb |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
